Last Updated: 08 Nov 2024
Executive Summary
Applied Therapeutics Inc. (APLT) is a clinical-stage biopharmaceutical company focused on developing novel treatments for cardiovascular disease, galactosemia, and diabetes complications. The company has a market capitalization of $1.13 billion and trades on the NASDAQ exchange.
Company Overview
Applied Therapeutics was founded in 2013 and is headquartered in New York City. The company has a pipeline of product candidates in various stages of development, including:
AT-007: A potential treatment for severe hypercholesterolemia
AT-008: A potential treatment for galactosemia
AT-009: A potential treatment for diabetic retinopathy
Fundamental Analysis
APLT's financial performance has been mixed in recent quarters. The company reported a net loss of $78.03 million in the most recent quarter, compared to a loss of $50.48 million in the same period last year. Revenue for the quarter was $333,000, down from $519,000 in the prior-year quarter.
The company's operating expenses have increased significantly in recent years, primarily due to increased spending on research and development. As a result, APLT has not yet achieved profitability.
Technical Analysis
APLT's stock price has been trending lower in recent months. The stock is currently trading below its 50-day and 200-day moving averages. The relative strength index (RSI) is also below 50, indicating that the stock is oversold.
Short Term Outlook
The short-term outlook for APLT is uncertain. The company's stock price is likely to remain volatile in the near term, as investors await news on the progress of its clinical trials.
Long Term Outlook
The long-term outlook for APLT is more positive. The company has a promising pipeline of product candidates, and if successful, these products could generate significant revenue in the future. However, investors should be aware that the development of new drugs is a risky and time-consuming process.
Analyst Recommendations
Analysts are generally positive on APLT's long-term prospects. Four analysts have a "Strong Buy" rating on the stock, while two have a "Buy" rating. The average analyst target price is $12.80.
